Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Aug 07, 2026
Why Is nLIGHT, Inc. (LASR) Stock Down -20.40% Today?

Why Is nLIGHT, Inc. (LASR) Stock Down -20.40% Today?

Key Takeaways

  • nLIGHT shares plummeted 20.40% to $60.05 in Thursday's session, extending an after-hours sell-off triggered by the company's second-quarter earnings report.
  • The primary catalyst was disappointing Q3 guidance, particularly an adjusted EBITDA midpoint of $4 million that fell well below Wall Street's $7.7 million consensus estimate.
  • Supply chain disruptions tied to China's heightened scrutiny of dual-use products are expected to defer approximately $17 million in product revenue from the third quarter, severely compressing near-term profitability.
  • The sell-off overshadowed an otherwise strong Q2 that featured record revenue of $82.6 million, up 34% year-over-year, and a non-GAAP EPS beat of $0.15 versus $0.14 expected.
  • Broader market sentiment around defense and semiconductor names was mixed, with investors punishing execution-risk stories despite healthy long-term demand signals.
  • Traders are now watching for updates on supply chain mitigation timelines, the ramp of the newly awarded JLWS defense contract, and any further analyst downgrades.

Opening Summary

LASR, the ticker for nLIGHT, Inc. — a designer and manufacturer of high-power semiconductor and fiber lasers serving the aerospace & defense, industrial, and microfabrication sectors — experienced a sharp sell-off on Thursday. Shares tumbled 20.40% to $60.05, down from a previous session close of $75.44. The decline was triggered by the company's second-quarter 2026 earnings report, released after Wednesday's close. While headline Q2 results surpassed expectations on revenue and met estimates on earnings, a materially weaker-than-expected third-quarter outlook — driven by supply chain disruptions originating in China — spooked investors and prompted a wave of selling that carried into Thursday's regular trading session.

Q2 Earnings: A Tale of Two Narratives

nLIGHT posted record second-quarter revenue of $82.59 million, representing a 34% surge from the prior-year period and clearing the consensus estimate of approximately $78.9 million. Product revenue reached an all-time high of $59.4 million, up 45% year-over-year, fueled primarily by the aerospace and defense segment, which saw product sales leap 72%. On a non-GAAP basis, the company earned $0.15 per diluted share, edging past the $0.14 consensus. Adjusted EBITDA nearly doubled to $10.7 million, and operating cash flow hit a record $20.7 million. By almost every backward-looking metric, nLIGHT delivered a standout quarter that reinforced management's narrative of accelerating demand for directed-energy laser systems, missile sensing, and advanced defense applications.

The Guidance Shock: Q3 Outlook Disappoints

The problem was not what nLIGHT reported — it was what the company forecast. Management guided third-quarter revenue to a range of $63 million to $73 million, a midpoint of $68 million that was roughly in line with Street estimates. However, the company disclosed that approximately $17 million in product revenue originally expected in Q3 would be deferred to future quarters. Even more concerning for investors was the adjusted EBITDA guidance of just $4 million at the midpoint, a figure less than half the $7.7 million analysts had projected. The steep sequential decline reflects the revenue deferral, a less favorable product mix, and continued margin pressure tied to the exit from lower-margin commercial cutting and welding applications. The combination of these factors reshaped the near-term earnings profile overnight.

China Supply Chain Disruptions: The Core Concern

The deferred revenue stems from a rapidly developing supply chain challenge: Chinese regulatory authorities have intensified scrutiny of dual-use products — goods with both commercial and military applications — particularly in the optics supply chain. China controls an outsized share of global optics manufacturing capacity, and nLIGHT, which sources certain optical components from Chinese suppliers, is now facing delays in clearing shipments. While management emphasized that the impact is concentrated in the commercial portion of the business rather than the defense segment, the reality that missing just a few components can halt entire production lines means the disruption is both operationally significant and difficult to predict. CEO Scott Keeney acknowledged on the earnings call that resolution could take weeks or potentially quarters, introducing considerable uncertainty into fourth-quarter execution as well.

Market Context and Trading Activity

The magnitude of the sell-off — a more than 20% single-day decline — was amplified by the stock's strong run-up in preceding months. LASR had surged over 268% in the twelve months prior to the report, driven by accelerating defense revenue, the HADES high-energy laser platform, and expanding directed-energy program wins including the recent Joint Laser Weapons System (JLWS) contract with a ceiling exceeding $600 million. With expectations elevated and the stock priced for flawless execution, the guidance shortfall triggered an aggressive repricing. Trading volume surged well above average, indicating institutional repositioning. Broader defense and semiconductor indices showed mixed signals, suggesting the move was overwhelmingly company-specific rather than macro-driven.

What Comes Next for LASR

The near-term trajectory for LASR hinges on the pace at which management can resolve or mitigate the optics supply chain disruption. The company has indicated it is pursuing alternative sourcing strategies and working with suppliers to expedite clearances, but no firm timeline has been offered. On the demand side, the long-term thesis remains intact: the JLWS award positions nLIGHT for a significant revenue ramp in 2027, and restocking of kinetic munitions continues to drive growth in the sensing and missile guidance segments. However, until visibility on the supply chain front improves, the stock may remain under pressure. Investors will closely monitor any updates from management and the next quarterly report for evidence that the deferred revenue is being recovered rather than permanently lost.

Trending AI Robots

For traders seeking to navigate fast-moving markets like the one impacting LASR today, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron provides hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions are featured in this dynamic, data-driven section. These bots vary by trading strategy, time horizon, performance metrics, and the symbols they trade, giving traders a diverse set of tools to explore. Visit the Trending AI Robots page to discover which automated strategies are thriving in today's environment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: LASR

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


Aroon Indicator for LASR shows an upward move is likely

LASR's Aroon Indicator triggered a bullish signal on August 06, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 266 similar instances where the Aroon Indicator showed a similar pattern. In of the 266 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where LASR advanced for three days, in of 298 cases, the price rose further within the following month. The odds of a continued upward trend are .

LASR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 58 cases where LASR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on August 07, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LASR as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for LASR turned negative on August 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .

LASR moved below its 50-day moving average on August 07, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for LASR crossed bearishly below the 50-day moving average on August 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LASR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LASR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.199) is normal, around the industry mean (8.592). P/E Ratio (0.000) is within average values for comparable stocks, (166.955). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.982). LASR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.014). P/S Ratio (9.597) is also within normal values, averaging (48.981).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are NVIDIA Corp (NASDAQ:NVDA), Broadcom Inc. (NASDAQ:AVGO), Taiwan Semiconductor Manufacturing Company Ltd (NYSE:TSM), Micron Technology (NASDAQ:MU), Advanced Micro Devices (NASDAQ:AMD), Intel Corp (NASDAQ:INTC), Texas Instruments (NASDAQ:TXN), Marvell Technology (NASDAQ:MRVL), Analog Devices (NASDAQ:ADI), QUALCOMM (NASDAQ:QCOM).

Industry description

The semiconductor industry manufacturers all chip-related products, including research and development. These chips are used in innumerable electronic devices, including computers, cell phones, smartphones, and GPSs. Intel Corporation, NVIDIA Corp., and Broadcomm are some of the prominent players in this industry. Semiconductor companies usually tend to do well during periods of healthy economic growth, thereby inducing further research and development in the industry – which in turn augurs well for productivity and growth in the economy. In the near future, demand for semiconductor products (and possibly innovation within the segment) should only expand further, with the proliferation of 5G, autonomous vehicles, IoT, and various AI-driven electronics set to herald a new, advanced chapter in the technology-driven world as we know it. With burgeoning prospects comes great competition. In 2015, SIA estimated that U.S. semiconductor industry ranks as the second most competitive U.S. industry out of 2882 U.S. industries designated manufacturers by the U.S. Census Bureau.

Market Cap

The average market capitalization across the Semiconductors Industry is 191.08B. The market cap for tickers in the group ranges from 13.43K to 5.42T. NVDA holds the highest valuation in this group at 5.42T. The lowest valued company is CYBL at 13.43K.

High and low price notable news

The average weekly price growth across all stocks in the Semiconductors Industry was 11%. For the same Industry, the average monthly price growth was -2%, and the average quarterly price growth was 48%. SITM experienced the highest price growth at 30%, while ON experienced the biggest fall at -6%.

Volume

The average weekly volume growth across all stocks in the Semiconductors Industry was -34%. For the same stocks of the Industry, the average monthly volume growth was -31% and the average quarterly volume growth was -62%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 53
Price Growth Rating: 47
SMR Rating: 75
Profit Risk Rating: 72
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
LASR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a manufacturer of semiconductor diode laser components

Industry Semiconductors

Profile
Details
Industry
Semiconductors
Address
4637 North West 18th Avenue
Phone
+1 360 566-4460
Employees
800
Web
https://www.nlight.net
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.